Literature DB >> 25990133

Long-Term Patency and Clinical Analysis of Expanded Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunt Stent Grafts.

Charles N Weber1, Gregory J Nadolski2, Sarah B White3, Timothy W I Clark4, Jeffrey I Mondschein2, S William Stavropoulos2, Richard D Shlansky-Goldberg2, Scott O Trerotola2, Michael C Soulen2.   

Abstract

PURPOSE: To evaluate long-term patency and symptomatic recurrence rates following transjugular intrahepatic portosystemic shunt (TIPS) creation with expanded polytetrafluoroethylene (ePTFE)-covered stent grafts and to determine the necessity of extended clinical follow-up beyond 2 years after TIPS creation.
MATERIALS AND METHODS: A retrospective review including 262 TIPSs created with ePTFE-covered stent grafts between July 2002 and October 2012 was performed. Primary, primary assisted, and secondary patency rates were calculated. Assessment of clinical data included technical, hemodynamic, and clinical success rates, as well as mortality after TIPS creation.
RESULTS: Primary patency rates at 2, 4, and 6 years were 74%, 62%, and 50%, respectively. Primary assisted patency rates at 2, 4, and 6 years were 93%, 85%, and 78%, respectively. Secondary patency rates at 2, 4, and 6 years were 99%, 91%, and 84%, respectively. Technical and hemodynamic success rates were 99% and 93%, respectively. Clinical success rates for refractory ascites were 66% (complete response) and 90% (partial response); clinical success rate for bleeding/varices was 90%. Mortality rates at 2, 4, and 6 years after TIPS creation were 27%, 38%, and 46%, respectively. At the median wait time until transplantation, patients had an 84% chance of being alive. TIPS dysfunction developed in 21% of patients; 30% of revisions occurred later than 2 years during follow-up.
CONCLUSIONS: Beyond 2 years after TIPS creation, patency rates gradually decrease, mortality rates continue to increase, and the chance of recurrent ascites or bleeding remains present. Together, these findings suggest that continued clinical follow-up beyond 2 years is necessary in patients with a TIPS created with an ePTFE-covered stent graft.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25990133     DOI: 10.1016/j.jvir.2015.04.005

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  19 in total

1.  Comparison of TIPS alone and combined with partial splenic embolization (PSE) for the management of variceal bleeding.

Authors:  Yue-Meng Wan; Yu-Hua Li; Zhi-Yuan Xu; Hua-Mei Wu; Xi-Nan Wu; Ying Xu
Journal:  Eur Radiol       Date:  2019-02-22       Impact factor: 5.315

2.  Combined Y-configured stents for revising occluded transjugular intrahepatic portosystemic shunt.

Authors:  Xiaoze Wang; Yongjun Zhu; Ming Zhu; Xuefeng Luo; Li Yang
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

3.  Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.

Authors:  Bin Qiu; Meng-Fei Zhao; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Fu-Liang He; Shan Dai; Jian-Nan Yao; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 4.  Chylous Ascites and Lymphoceles: Evaluation and Interventions.

Authors:  Ernesto Santos; Amgad M Moussa
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 5.  Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment.

Authors:  Richa Bhardwaj; Haleh Vaziri; Arun Gautam; Enrique Ballesteros; David Karimeddini; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2017-12-04

6.  Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results.

Authors:  Barbara Geeroms; Wim Laleman; Annouschka Laenen; Sam Heye; Chris Verslype; Schalk van der Merwe; Frederik Nevens; Geert Maleux
Journal:  Eur Radiol       Date:  2016-09-15       Impact factor: 5.315

7.  Transjugular Intrahepatic Portosystemic Shunt Dysfunction: Concordance of Clinical Findings, Doppler Ultrasound Examination, and Shunt Venography.

Authors:  Joshua M Owen; Ron Charles Gaba
Journal:  J Clin Imaging Sci       Date:  2016-07-18

8.  Effect of initial stent position on patency of transjugular intrahepatic portosystemic shunt.

Authors:  Shi-Hua Luo; Jian-Guo Chu; He Huang; Ke-Chun Yao
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

9.  Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes.

Authors:  Michael C Hsu; Charles N Weber; S William Stavropoulos; Timothy W Clark; Scott O Trerotola; Richard D Shlansky-Goldberg; Michael C Soulen; Gregory J Nadolski
Journal:  World J Hepatol       Date:  2017-04-28

10.  Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy.

Authors:  Hong-Bin Li; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Fu-Liang He; Xiao-Qun Dong; Fu-Quan Liu
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.